Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Baxdrostat on Ambulatory Blood Pressure in Resistant Hypertension
2023-507640-36-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in resistant hypertension (RH) comparing Baxdrostat with Placebo (2 arms). Primary endpoint: Change from baseline in ambulatory 24-hour average systolic blood pressure at Week 12. Started Apr 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on 2023-507640-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507640-36-00.